Objective {#sec1}
=========

The first cases of the novel coronavirus (sever acute respiratory syndrome coronavirus 2 \[SARS-CoV-2\]) infection were reported in Wuhan in December 2019.[@bib1] More than 12.1 million people have been infected with over 550,000 deaths. These cases include an increasing number of pregnant women; however, we are still relatively early in our understanding of the severity of the disease on pregnancy. Early reports focused solely on the fetal risks; however, the emphasis has correctly shifted toward maternal health.[@bib2], [@bib3], [@bib4], [@bib5], [@bib6] A recent study reported a hospitalization rate of 52%, including a rate of 10% in intensive care unit (ICU) admission.[@bib5] Nevertheless, the available literature is somewhat conflicting with some studies suggesting that pregnancy is not associated with markers of disease severity and others reporting worse outcomes. This contradiction implies the need for larger and more methodologically robust matched case-control studies to clarify the association between pregnancy and the coronavirus disease 2019 (COVID-19). The objective of our study was to compare the clinical outcomes and laboratory findings of pregnant women at ≥20 weeks' gestation infected with SARS-CoV-2 with a cohort of nonpregnant women with a confirmed diagnosis of COVID-19 after closely matching the 2 groups using a propensity score.

Study Design {#sec2}
============

This was a retrospective study conducted in the following 4 large university hospitals in France and Belgium between January 1, 2020, and May 13, 2020: (1) Antoine Béclère, Clamart, Paris, France; (2) Bicêtre Hospital, Le Kremlin-Bicêtre, France; (3) Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France; and (4) Brugmann University Hospital, Brussels, Belgium. The study received ethical approval from the Brugmann University Hospital ethics committee (Comité d\'Ethique 2020/88) and the institutional review board of the French College of Obstetricians and Gynecologists (Comité d\'Ethique de la Recherche en Obstétrique et Gynécologie OBS-2020-0402). Inclusion criterion was female patients of reproductive age with positive SARS-CoV-2 infection confirmed by real-time polymerase chain reaction tests of nasopharyngeal swab samples. Included patients were then divided into the following 2 groups: group 1, nonpregnant controls, and group 2, pregnant cases. The primary outcome was admission to the ICU. The secondary outcomes included hospitalization for clinical deterioration, need for supplemental oxygen therapy (OT), and endotracheal intubation (ETI). The following variables were analyzed: patient age, ethnicity, weight, height, body mass index (BMI), preexisting medical conditions (diabetes mellitus types I and II, hypertension, and asthma), symptoms, physical examination, pregnancy status, and gestational age at the initial presentation. Laboratory tests analyzed included hemoglobin, white blood cell count (WBC), platelet count, absolute neutrophil and lymphocyte counts, liver function tests (alanine transaminase \[ALT\], aspartate transaminase \[AST\]), lactate dehydrogenase, fibrinogen, and D-dimers coagulation tests. All data were anonymized. Hospitalization for clinical deterioration was defined as an admission to a regular care facility, a dedicated COVID-19 ward, or an ICU owing to complications directly related to a confirmed COVID-19 diagnosis. Common reasons for admission included severe dyspnea, desaturation (oxygen saturation of \<95% in room air), and sepsis. Hospital admissions for problems other than those reflecting a deteriorating condition were excluded. In all cases, pregnancy was confirmed using high-resolution abdominal or vaginal ultrasonography. Maternal weights used were those from the booking visit. Lymphocytopenia was defined as an absolute lymphocyte count of \<1×10^9^ cells/L. An activated partial thromboplastin ratio level of \>1.2 was considered as abnormal. Data were analyzed with the statistical software package Statistical Product and Service Solutions (version 25.0, IBM SPSS Statistics; SPSS Inc, Chicago, IL), R (version 3.6.2, R Core Team, 2019), and Excel (version 15.0; Microsoft, Redmond, WA). We used the Fisher's exact test to compare the proportions of binomial categorical variables. After checking the normal distribution of continuous variables, we used the Student *t* test or the Mann--Whitney U test to compare their means in the 2 groups of the study. We undertook a propensity score analysis to match women between the 2 groups. The covariate balancing propensity score R package and survey R packages were used to determine the propensity score as previously described.[@bib7] A 2-sided *P*\<.05 was considered to be statistically significant.

Results {#sec3}
=======

A total of 201 patients met the inclusion criteria. In addition, the following 11 patients were excluded from the study: 6 nonpregnant patients (4 receiving hemodialysis, 1 patient affected by trisomy 21, and 1 patient with complex congenital heart disease) and 5 pregnant patients (all at \<20 weeks' gestation). This left 190 eligible patients for the final analysis who were divided into the following 2 groups: a nonpregnant control group 1 (107 of 190 patients) and the pregnant case group 2 (83 of 190 patients). [Table 1](#tbl1){ref-type="table"} indicates the propensity score matching for a variety of predefined variables. The first part of the table (before matching) indicates that, in almost all cases, the 2 groups had different means or proportions for the different variables before matching was applied. The mean age in the control group was significantly higher than that in the case group (36.46±6.89 vs 31.97±6.24 years; *P*\<.001), but no statistically significant differences were observed for BMI or comorbidities between the 2 groups. The second part of the table presents the results after matching in which we observe that the means, standard deviations, and the proportions are now much closer between the 2 groups. The absolute standardized difference values are equal to 0, indicating that the 2 groups now had similar means or proportions for the different variables after matching was applied. Based on this matching table, we consider the nonpregnant and pregnant groups to be similar on covariates chosen for the propensity score. [Table 2](#tbl2){ref-type="table"} presents the differences between the control and case groups in relation to the symptoms and laboratory test results at presentation. The incidences of fever and cough did not differ significantly between the 2 groups (57.8% vs 60.6% \[*P*=.765\] and 78.3% vs 73.1% \[*P*=.495\], respectively). Nevertheless, dyspnea, anosmia or ageusia, fatigue and myalgia, upper respiratory tract symptoms, gastrointestinal symptoms, and other symptoms, such as headache, chest discomfort, and cutaneous rash, were all significantly lower in pregnant women. Moreover, there was significant difference of hemoglobin level, AST, ALT, C-reactive protein (CRP), creatinine, and D-dimers between the 2 groups. Other laboratory test results were similar in both the groups. [Table 3](#tbl3){ref-type="table"} presents the comparison of primary and secondary outcomes between the 2 groups of the study after applying the propensity score matching and performing a series of logistic regressions. Pregnant women were at higher risk for ICU admission than nonpregnant women (11.08% vs 2.38%; *P*=.024). In addition, they were also at higher risk for hospital admission because of COVID-19 respiratory decompensation such as dyspnea and hypoxemia (58.21% vs 17.4%; *P*\<.001), for the need for OT (36.04% vs 17.24%; *P*=.006), and for ETI (10.16% vs 1.67%; *P*=.022). However, there were no cases of mortality in either of the 2 groups.Table 1Propensity score matching for age, body mass index, and comorbidities in case and control groupsVariableBefore matchingAfter matchingControl group 1 (n=107)Case group 2 (n=83)ASD*P* valueControl group 1 (n=107)Case group 2 (n=83)ASDAge, y36.46±6.8931.97±6.2468.26.00134.17±7.3734.17±6.490.00DM (type I or II)4.674.820.691.0004.244.240.00Hypertension7.484.8211.08.5565.605.600.00Asthma10.288.436.34.8048.348.340.00BMI, kg/m^2^28.25±6.3027.97±6.414.40.75228.02±6.2528.02±6.630.00[^1][^2][^3]Table 2Comparison of symptoms and laboratory test results at presentation between the 2 groupsSymptomControl group 1 (n=107)Case group 2 (n=83)*P* valueSymptoms at presentation Fever63 (60.6)48 (57.8).765 Cough76 (73.1)65 (78.3).495 Dyspnea46 (44.7)25 (30.1).049 Anosmia or ageusia36 (34.6)15 (18.1).013 Fatigue and myalgia70 (67.3)26 (31.3)\<.001 URT symptoms (runny nose, blocked nose, sore throat)41 (39.4)9 (10.8)\<.001 Gastrointestinal symptoms (diarrhea, abdominal pain, nausea, vomiting)22 (21.2)8 (9.6).044 Others (headache, chest discomfort, cutaneous rash)44 (42.3)10 (12.0)\<.001Laboratory tests Hemoglobin, g/dL12.98±1.6911.23±1.32\<.001 Platelet count, ×10^9^/L236.91±123.39228.97±92.55.896 WBC count, ×10^9^/L6.93±4.557.49±3.38.066 Lymphocyte count, ×10^9^/L1.45±0.811.17±0.51.116 Lymphocytopenia13 (29.5)31 (45.6).114 Neutrophil count, ×10^9^/L4.74±3.973.84±3.26.876 Prothrombin time activity, %97.46±13.55102.40±11.28.160 aPTT ratio1.05±0.181.08±0.22.131 Abnormal aPTT5 (13.5)19 (31.1).056 Fibrinogen, mg/dL513.25±135.07488.56±133.43.339 AST, IU/L47.97±36.6035.49±23.85.004 ALT, IU/L45.50±40.4427.84±30.51\<.001 CRP, mg/dL73.50±78.2334.17±37.10.014 Creatinine, mg/L0.69±0.160.61±0.41\<.001 LDH, IU/L320.08±119.48246.00±4.58.396 D-dimers, ng/mL781.50±508.581112.00±388.69.046[^4][^5][^6]Table 3Comparison of primary and secondary outcomes between the 2 groups after applying the propensity score matchingVariableControl group 1 (n=107)Case group 2 (n=83)Adjusted *P* valuePrimary outcome ICU admission2.3811.08.024Secondary outcomes Hospital admission for COVID-1917.458.21\<.001 Need for oxygen therapy17.2436.04.006 Endotracheal intubation1.6710.16.022[^7][^8][^9]

Conclusion {#sec4}
==========

Our propensity score--matched case-control study has indicated that pregnant women diagnosed with COVID-19 at ≥20 weeks' gestation have more severe outcomes than their nonpregnant counterparts. A small number of case-control studies have been published, but few of those have attempted to match cases against the controls for a variety of parameters and demographic features. Liu et al[@bib2] observed that pregnant women had low fever at presentation, higher WBC counts, and more consolidation on chest computed tomography scans. Blitz et al[@bib3] described that among hospitalized women who received a diagnosis of COVID-19, pregnant women are not at increased risk for ICU admission. Qiancheng et al[@bib4] reported that pregnancy was not associated with increased severity of the disease, shorter virus clearance time, or longer hospital stay after comparing 28 cases to 54 controls. On the contrary, significant maternal mortality has been documented in a cohort of patients from Iran.[@bib6] These studies indicate not only the difficulties in determining the absolute risk of clinical deterioration specifically related to pregnancy but also the importance of correct case and control group matching. In our study, we reported that pregnant women had higher rates of ICU admission and need for supplemental OT and ETI than nonpregnant women. This is the first multicenter case-control study of COVID-19 in pregnancy using a propensity score. We have included a relatively high number of pregnant women in the study, almost matching the number of available controls, lending more validity to the strength of our findings. However, as with all retrospective designs, there are certain limitations. These include missing data of laboratory examinations, making it difficult to evaluate more deeply the differences between the pregnant and nonpregnant populations. One relevant criticism could be that the threshold for diagnostic evaluation, hospitalization, and certain treatments may in fact be lower for pregnant women than for others, which may have biased our finding of increased disease severity in this group. However, the participating centers involved did not drastically alter their management of patients with COVID-19 on the basis of pregnancy, except in cases of deterioration during the third trimester, when emergency delivery was sometimes needed to alleviate the additional physiological demands of pregnancy (data not indicated in this study). Based on this study and those of some other groups,[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6] we advise clinicians to exercise prudence when planning the management of pregnant women diagnosed with COVID-19, particularly in the latter half of the pregnancy, when maternal risk of clinical decompensation and complications may be higher.
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